Clinical trial Recruiting at 1 site Observational Ages 18 and up

Heart monitoring for cancer patients receiving chemotherapy and targeted drugs

Official title: Development of an Active Surveillance System for Adverse Reactions to Molecular Targeted Drugs Based on Biomarkers and Personalized Medicine and Its Impact on Patient Quality of Life

Run by Sixth Affiliated Hospital, Sun Yat-sen University · NCT07058454 · Data updated 2026-11-12

This project will test whether regular heart checks (blood biomarkers, ECG, and echocardiogram) can predict serious heart problems in adults getting chemotherapy or targeted cancer drugs.

More Breast Cancer trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment5000 (estimated)
SponsorSixth Affiliated Hospital, Sun Yat-sen University
Academic / other
Drugs / interventionschemotherapy, trastuzumab, bevacizumab
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedSeptember 1, 2025
Main results expectedSeptember 1, 2027
Study endsDecember 31, 2027
Registry record updatedDecember 29, 2025
Trial IDNCT07058454 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with a pathologically confirmed cancer who are receiving or planning to receive chemotherapy or targeted cancer therapies and are willing to provide informed consent and biological samples.

Probably not a fit

Patients with recent severe cardiovascular or cerebrovascular events, incomplete medical records, or who cannot complete planned chemotherapy or follow-up at the study center are unlikely to benefit from the study findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter observational effort to monitor cardiac outcomes in adults undergoing chemotherapy or molecularly targeted cancer therapies. Participants will undergo periodic cardiac evaluations including ECG, echocardiography, and biomarker testing (troponin T, NT‑proBNP), with blood samples collected for genomic analysis. Local factors (for example, central venous catheter–related thrombosis) and systemic factors (age, comorbidities, BMI, genetic variants) will be integrated to develop a predictive model for major adverse cardiovascular events (MACE). The study will also track the impact of cardiotoxicity and the monitoring strategy on patients' quality of life.

Why it matters

Potential benefit: If successful, the model could help detect heart damage earlier and guide personalized monitoring or treatment to reduce major cardiac events.

How similar studies have gone: Previous research has shown biomarkers like troponin and NT‑proBNP can detect early cardiotoxicity, but combining imaging, clinical and local catheter-related factors with genomics into a validated predictive model is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1.Adults (age \> 18 years) with a pathologically confirmed malignant tumor (any type of cancer); 2.Currently receiving or planning to receive chemotherapy (including regimens containing molecular targeted drugs) as adjuvant treatment for cancer; 3.Willing and able to participate in the study with provision of informed consent, and agreeable to provide required clinical data and biological samples.

\-

Exclusion Criteria:

1. Incomplete basic patient information or medical records (missing key data necessary for the study);
2. Failure to complete the full course of planned chemotherapy at the study center (e.g., patient did not adhere to or finish all cycles of adjuvant chemotherapy at our institution);
3. History of severe acute cardiovascular or cerebrovascular events within 6 months prior to enrollment, including acute heart failure, acute myocardial infarction, acute intracerebral hemorrhage (stroke), malignant arrhythmia, or New York Heart Association (NYHA) Class IV/V heart failure;
4. Missing essential pre- or post-chemotherapy evaluations: patients who did not undergo complete baseline or end-of-treatment assessments (such as blood routine, hepatic/renal function, coagulation profile, cardiac enzymes (troponin T), NT-proBNP (or BNP), 12-lead ECG, and echocardiogram)

Where it's running

  • Sixth Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.